LT3494134T - Rekombinantiniai polipeptidai ir jų panaudojimas - Google Patents

Rekombinantiniai polipeptidai ir jų panaudojimas

Info

Publication number
LT3494134T
LT3494134T LTEPPCT/US2017/045126T LTUS2017045126T LT3494134T LT 3494134 T LT3494134 T LT 3494134T LT US2017045126 T LTUS2017045126 T LT US2017045126T LT 3494134 T LT3494134 T LT 3494134T
Authority
LT
Lithuania
Prior art keywords
recombinant polypeptides
polypeptides
recombinant
Prior art date
Application number
LTEPPCT/US2017/045126T
Other languages
English (en)
Inventor
Karthik Viswanathan
Boopathy Ramakrishnan
Brian Booth
Kristin Narayan
Andrew Wollacott
Original Assignee
Visterra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra, Inc. filed Critical Visterra, Inc.
Publication of LT3494134T publication Critical patent/LT3494134T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
LTEPPCT/US2017/045126T 2016-08-02 2017-08-02 Rekombinantiniai polipeptidai ir jų panaudojimas LT3494134T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370201P 2016-08-02 2016-08-02
US201762485671P 2017-04-14 2017-04-14
PCT/US2017/045126 WO2018052556A1 (en) 2016-08-02 2017-08-02 Engineered polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
LT3494134T true LT3494134T (lt) 2026-02-25

Family

ID=59656189

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/045126T LT3494134T (lt) 2016-08-02 2017-08-02 Rekombinantiniai polipeptidai ir jų panaudojimas

Country Status (17)

Country Link
US (3) US11858980B2 (lt)
EP (1) EP3494134B1 (lt)
JP (2) JP7464389B2 (lt)
KR (2) KR20250036943A (lt)
CN (3) CN118085091A (lt)
AU (2) AU2017325654B2 (lt)
BR (1) BR112019001989A2 (lt)
CA (1) CA3032820A1 (lt)
CL (3) CL2019000261A1 (lt)
CO (1) CO2019000931A2 (lt)
DK (1) DK3494134T3 (lt)
FI (1) FI3494134T3 (lt)
IL (2) IL315729A (lt)
LT (1) LT3494134T (lt)
MX (1) MX2019001458A (lt)
SG (1) SG11201900616UA (lt)
WO (1) WO2018052556A1 (lt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618821A4 (en) 2010-09-24 2014-08-13 Brigham & Womens Hospital NANOSTRUCTURED GELS FOR CONTROLLED RELEASE OF CAPSUED MEDIUM
KR20250036943A (ko) 2016-08-02 2025-03-14 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
CN109863170B (zh) 2016-08-12 2024-08-16 詹森生物科技公司 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
CN109843916B (zh) * 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
EP3710482A4 (en) * 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
AU2019231191A1 (en) * 2018-03-05 2020-09-03 Institute Of Biophysics, Chinese Academy Of Sciences Methods of use of soluble CD24 for treating acquired immune deficiency syndrome (HIV/AIDS)
EP3773478A1 (en) 2018-04-04 2021-02-17 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
JP7372237B2 (ja) * 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
SG11202105365RA (en) * 2018-11-22 2021-06-29 Agency Science Tech & Res Modified fc region
AU2019404098A1 (en) 2018-12-18 2021-05-27 Boehringer Ingelheim Io Canada Inc. FLT3 agonist antibodies and uses thereof
EP3898667A2 (en) * 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
BR112021023483A2 (pt) * 2019-05-23 2022-02-08 Univ Xiamen Novo anticorpo anti-vírus da hepatite b e seus usos
WO2020257289A2 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
BR112022002494A2 (pt) * 2019-09-04 2022-06-28 Cedars Sinai Medical Center Uso de ctla4-ig livre de inibidor de calcineurina + anti-il6/il6r para imunossupressão em longo prazo em receptores de transplante de órgão sólido
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
WO2021119467A1 (en) 2019-12-11 2021-06-17 Visterra, Inc. Compositions and methods for treating and preventing influenza
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN111254207A (zh) * 2020-01-22 2020-06-09 郑州大学第一附属医院 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用
KR20230042273A (ko) 2020-06-24 2023-03-28 비스테라, 인크. April에 대한 항체 분자 및 그의 용도
MX2023006599A (es) 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
MX2023008302A (es) 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.
TW202245825A (zh) 2021-01-20 2022-12-01 美商威特拉公司 介白素-2藥劑及其用途
WO2022183053A1 (en) * 2021-02-25 2022-09-01 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
KR20250169356A (ko) 2021-12-01 2025-12-03 비스테라, 인크. 인터류킨-2 제제의 사용 방법
KR20240148001A (ko) 2022-02-11 2024-10-10 비스테라, 인크. 자가면역 질환의 치료를 위한 인터류킨-2 뮤테인
JP2025514142A (ja) 2022-04-25 2025-05-02 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
CN115028738B (zh) * 2022-06-14 2025-05-16 天津医科大学 一种Fc融合蛋白双重靶向降解剂及应用
WO2024027793A1 (en) * 2022-08-05 2024-02-08 I-Mab Biopharma (Hangzhou) Co., Ltd. Bispecific antibodies targeting ifnar1 and blys
WO2024097938A1 (en) * 2022-11-04 2024-05-10 Cephalon, LLC Compositions and methods for increasing transport into the brain
KR20250155048A (ko) * 2023-03-06 2025-10-29 조인트 스탁 컴퍼니 "바이오케드" 인간 CD1b (분화 클러스터 1) 단백질의 이종이량체를 포함하는 항체-유사 분자
WO2024211779A1 (en) * 2023-04-05 2024-10-10 The Regents Of The University Of California Affinity peptides for diagnosis and treatment of viral infections
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
US20260028384A1 (en) 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1572091A4 (en) 2002-07-09 2008-03-05 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
AU2012203476A1 (en) * 2003-11-12 2012-07-05 Biogen Idec Ma Inc. Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
ES2426817T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AU2015200990B2 (en) 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2011057198A1 (en) 2009-11-09 2011-05-12 Carson Cantwell G Vaccine testing system
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
KR102568454B1 (ko) * 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
JP6147670B2 (ja) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
JP6228014B2 (ja) 2011-02-07 2017-11-08 リサーチ ディベロップメント ファウンデーション 操作された免疫グロブリンＦｃポリペプチド
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
KR20140076593A (ko) 2011-09-30 2014-06-20 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
ES2751386T3 (es) * 2011-12-21 2020-03-31 Amgen Inc Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
MX366804B (es) * 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
TW202500756A (zh) 2012-02-24 2025-01-01 日商中外製藥股份有限公司 經FcγRIIB促進抗原消失之抗原結合分子
WO2013165690A1 (en) 2012-04-30 2013-11-07 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
JP6280300B2 (ja) 2012-08-24 2018-02-14 中外製薬株式会社 脳疾患治療剤
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
EP3628685A1 (en) * 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Human fcrn-binding modified antibodies and methods of use
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
FR3024453B1 (fr) 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
SI3215528T1 (sl) * 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
FR3035879B1 (fr) 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
CR20180445A (es) 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
KR20250036943A (ko) 2016-08-02 2025-03-14 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
ES2991804T3 (es) 2017-09-19 2024-12-04 Tillotts Pharma Ag Variantes de anticuerpos

Also Published As

Publication number Publication date
CN118388638A (zh) 2024-07-26
IL264590A (en) 2019-02-28
JP2022120132A (ja) 2022-08-17
CL2024003234A1 (es) 2025-03-07
US20180037634A1 (en) 2018-02-08
EP3494134A1 (en) 2019-06-12
CL2022000036A1 (es) 2022-10-28
FI3494134T3 (fi) 2026-02-19
EP3494134B1 (en) 2025-12-10
JP7464389B2 (ja) 2024-04-09
MX2019001458A (es) 2019-07-04
BR112019001989A2 (pt) 2019-08-20
CO2019000931A2 (es) 2019-02-08
JP2019531705A (ja) 2019-11-07
CL2019000261A1 (es) 2019-06-28
IL315729A (en) 2024-11-01
AU2017325654B2 (en) 2024-09-05
AU2024270619A1 (en) 2025-01-02
WO2018052556A8 (en) 2019-03-14
IL264590B1 (en) 2025-12-01
US20250296982A1 (en) 2025-09-25
CN118085091A (zh) 2024-05-28
US20200277358A1 (en) 2020-09-03
KR102777127B1 (ko) 2025-03-07
WO2018052556A1 (en) 2018-03-22
DK3494134T3 (da) 2026-02-09
AU2017325654A1 (en) 2019-02-14
SG11201900616UA (en) 2019-02-27
US11858980B2 (en) 2024-01-02
RU2019104889A3 (lt) 2020-09-04
CN110072887A (zh) 2019-07-30
RU2019104889A (ru) 2020-09-04
CA3032820A1 (en) 2018-03-22
KR20190038607A (ko) 2019-04-08
KR20250036943A (ko) 2025-03-14

Similar Documents

Publication Publication Date Title
LT3494134T (lt) Rekombinantiniai polipeptidai ir jų panaudojimas
IL281273A (en) Adapted 21–FGF polypeptides and their uses
EP3684816C0 (en) CHIMERIC POLYPEPTIDES AND THEIR USES
IL268593A (en) Polypeptide variants and uses thereof
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
LT3484865T (lt) Somatostatino moduliatoriai ir jų panaudojimas
LT3498292T (lt) Uspa2 baltymo konstruktai ir jų panaudojimas
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
EP3405222C0 (en) Novel polypeptides and medical uses thereof
LT3290441T (lt) Rgma surišantys baltymai ir jų panaudojimas
GB201620658D0 (en) Recombinant yeast and use thereof
EP4163354C0 (en) POLYPEPTIDES EXHIBITING PHOSPHOLIPASE C ACTIVITY AND POLYNUCLEOTIDES CODED FOR THESE
LT3337506T (lt) Deriniai ir jų panaudojimas
EP3723771A4 (en) Recombinant adenoviruses and uses thereof
LT3512849T (lt) 7-pakeistieji 1-aril-naftiridin-3-karboksamidai ir jų naudojimas
LT3060660T (lt) Rekombinantiniai glikoproteinai ir jų naudojimas
EP3630795A4 (en) MODIFIED ALDOLASE POLYPEPTIDES AND THEIR USES
DK3445778T3 (da) Pegylerede bioaktive peptider og anvendelser deraf
DK3630793T3 (da) Rekombinant protein
DK3438118T3 (da) Peptidderivat og anvendelse deraf
GB201613142D0 (en) Polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof